Syros Capital Lease Obligations from 2010 to 2024
| SYRS Stock | USD 0.28 0.08 22.22% |
Capital Lease Obligations | First Reported 2016-06-30 | Previous Quarter 20.3 M | Current Value 19.7 M | Quarterly Volatility 11.6 M |
Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 5.4 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 21.1, Dividend Yield of 0.0 or PTB Ratio of 13.91. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.
Syros | Capital Lease Obligations |
Latest Syros Pharmaceuticals' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Syros Pharmaceuticals over the last few years. Syros Pharmaceuticals capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Syros Pharmaceuticals asset purchases. For example, Syros Pharmaceuticals can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Syros Pharmaceuticals control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Syros Pharmaceuticals' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Syros Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 9,309,127 | |
| Geometric Mean | 1,124,650 | |
| Coefficient Of Variation | 126.60 | |
| Mean Deviation | 10,953,485 | |
| Median | 221,000 | |
| Standard Deviation | 11,785,133 | |
| Sample Variance | 138.9T | |
| Range | 26.6M | |
| R-Value | 0.79 | |
| Mean Square Error | 56.5T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 2,079,119 | |
| Total Sum of Squares | 1944.5T |
Syros Capital Lease Obligations History
About Syros Pharmaceuticals Financial Statements
Syros Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Syros Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Syros Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 20.9 M | 16.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.